Partner Courtenay Brinckerhoff was quoted in the Law360 article, “These 10 Decisions Remade the Patent Landscape,” where she discussed the implications of Nautilus v. Biosig Instruments.
In this 2014 ruling, the U.S. Supreme Court discarded a Federal Circuit test that made it difficult to invalidate patents as indefinite, bolstering the defense for accused infringers. “When I first started practicing, you wouldn’t even consider that you could invalidate a patent claim based on indefiniteness. Now it’s definitely something that you would look at in every case,” said Brinckerhoff, who described Nautilus as one of a series of rulings that set a “trend of really deeply scrutinizing the validity of patents.
In this 2014 ruling, the U.S. Supreme Court discarded a Federal Circuit test that made it difficult to invalidate patents as indefinite, bolstering the defense for accused infringers. “When I first started practicing, you wouldn’t even consider that you could invalidate a patent claim based on indefiniteness. Now it’s definitely something that you would look at in every case,” said Brinckerhoff, who described Nautilus as one of a series of rulings that set a “trend of really deeply scrutinizing the validity of patents.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”